Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.20 Britannia Life Science Center Lease, Dated As of April 28, 2016, by and Among Blade Therapeutics, Inc. and Bayside Acquisition, LLC
- 10.21 First Amendment to Lease, Dated As of October 15, 2021, by and Among Blade Therapeutics, Inc. and Bayside Acquisition, LLC
- 10.22 Sublease Agreement, Dated As of October 1, 2019, by and Among Blade Therapeutics, Inc. and Molecular Transport Inc.
- 21.1 List of Subsidiaries of the Registrant
- 23.1 Consent of Marcum LLP
- 23.2 Consent of Ernst and Young LLP, Independent Registered Accounting Firm for Blade Therapeutics, Inc
- 99.1 Form of Proxy Card for Extraordinary General Meeting
- 99.9 Consent of Vantage Point Advisors, Inc.
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 17 Jun 22 RW Registration withdrawal request
- 23 May 22 424B3 Prospectus supplement
- 10 May 22 EFFECT Notice of effectiveness
- 9 May 22 424B3 Prospectus supplement
- 9 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Mar 22 S-4 Registration of securities issued in business combination transactions
BIOT similar filings
- 3 May 22 Registration of securities issued in business combination transactions (amended)
- 15 Apr 22 Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 Registration of securities issued in business combination transactions (amended)
- 15 Mar 22 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 15, 2022, with respect to the consolidated financial statements of Blade Therapeutics, Inc. included in the proxy statement/prospectus of Biotech Acquisition Company that is made a part of the Registration Statement (Form S-4) and Prospectus of Biotech Acquisition Company for the registration of its common stock.
/s/ Ernst & Young LLP
Redwood City, California
March 15, 2022